Presented at a symposium in honour of Lawrie Beilin held in conjunction with the High Blood Pressure Research Council of Australia Annual Scientific Meeting, Melbourne, 6–7 December 2005. The papers in these proceedings have been peer reviewed.
OMEGA-3 FATTY ACIDS AND HYPERTENSION IN HUMANS
Article first published online: 10 AUG 2006
Clinical and Experimental Pharmacology and Physiology
Volume 33, Issue 9, pages 842–846, September 2006
How to Cite
Mori, T. A. (2006), OMEGA-3 FATTY ACIDS AND HYPERTENSION IN HUMANS. Clinical and Experimental Pharmacology and Physiology, 33: 842–846. doi: 10.1111/j.1440-1681.2006.04451.x
- Issue published online: 10 AUG 2006
- Article first published online: 10 AUG 2006
- Received 15 December 2005; revision 27 February 2006; accepted 13 March 2006.
- cardiovascular disease;
- docosahexaenoic acid;
- eicosapentaenoic acid;
- fish oils;
- ω3 fatty acids
- 1Population studies and clinical trials provide compelling evidence that omega-3 (w3) fatty acids have cardioprotective effects. The strongest evidence is from DART and GISSI-P, two secondary prevention trials in patients with previous myocardial infarctions. Data from these trials support a reduction in ventricular fibrillation as a primary mechanism for the decreased incidence of myocardial infarction.
- 2Evidence suggests that w3 fatty acids may also provide protection against stroke, particularly ischaemic stroke.
- 3The cardioprotective effects of w3 fatty acids relate to improvements in blood pressure, cardiac function, arterial compliance and vascular function, as well as improved lipid metabolism, antiplatelet and anti-inflammatory effects.
- 4Clinical trials in humans have shown that eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have different haemodynamic properties. Docosahexaenoic acid may be more favourable in lowering blood pressure and heart rate, as well as improving vascular function. However, the effects of EPA and DHA may also differ depending on the target population.